Clinical Trial Update: Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with temozolomide in neuroendocrine tumors has completed enrollment. The document does not report trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Bevacizumab (bevacizumab)
• Temodar (Temozolomide)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED